Advancing Animal Cell Technology and Biopharma R&D in Japan: iBET at JAACT2025
Debottlenecking Vaccine Design and Stem Cell Bioengineering
iBET highlights the recent participation of António Roldão and Margarida Serra, leading scientists in Animal Cell Technology, at JAACT2025 – Japanese Association for Animal Cell Technology, held in Osaka, Japan (December 8-11).
António Roldão (Head of the Cell-based Vaccines Development Lab & Coordinator of Late-Stage R&D Unit at iBET) delivered a presentation on “Debottlenecking Vaccine Design and Manufacturing”.
His talk provided an overview of iBET’s holistic strategy to address cell culture–based vaccine development and manufacturing. This integrated approach encompasses upstream, downstream, process intensification and integration, as well as vector and vaccine design.
Margarida Serra (Head of the Stem and Immune Cells Bioengineering Lab at iBET) presented recent work on Billion-scale Production of Functional hiPSC-derived Cardiomyocytes and Extracellular Vesicles in Bioreactors: Bridging Stem Cell Biology and Engineering Strategies.
António Roldão and Margarida Serra present iBET’s animal cell technology R&D at JAACT2025.
JAACT2025 gathered world-leading scientists to discuss the future of cell manufacturing, digital and data-driven cell-culture engineering, advanced bioproduction platforms and innovations in rAAV manufacturing: reinforcing the foundations of bioproduction and regenerative medicine.
From left to right: António Roldão, Prof. Takeshi Omasa (Chairperson of JAACT2025 Meeting), Prof. Yoshinori Katakura (Chair of JAACT), and Prof. Terry Papoutsakis (University of Delaware, USA) at JAACT2025.
iBET’s participation reflects our commitment in Animal Cell Technology R&D to advancing breakthrough research in vaccine design, bioproduction, and stem cell technologies through global scientific collaboration.
